This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Migraine Drug Results Will Cure Stock Headache Says Alder CEO

10/08/15 10:58 AM EDT
After a stunning summer surge, shares of Alder Biopharmaceuticals (ALDR) have become a headache for its owners, tumbling over 32% in the past three months. Upcoming results about its migraine drug will hopefully ease their pain, said the immunotherapy company’s CEO Dr. Randall Schatzman. 'We’ve just initiated the last stage of our clinical trial campaign and the first of our pivotal trials. But we’ve got a couple of other trials that are ongoing that we are just finishing up now,' said Schatzman. 'We will be reporting data on those in the first quarter of 2016. I think those will be significant in terms of highlighting the better way to treat these patients.' Alder’s drug is based on a molecule which the company refers to as ALD403. It is a monoclonal antibody to a small neuropeptide transmitter called calcitonin gene-related peptide, or CGRP. Schatzman said it is an important molecule in terms of both the initiation and the propagation of the signal that actually starts a migraine and advances that into the central nervous system. 'There are 36 million migraine sufferers in the United State alone today and about 18 million of those are candidates for the Alder drug,' said Schatzman, adding that that the $428 million the company has in cash will get it through the next significant set of studies allow it to apply for licensure with the FDA.
Stocks in this video: ALDR
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.

Select the service that is right for you!

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Growth Seeker

Chris Versace, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Daily Swing Trade

Master swing trader Alan Farley uses his sophisticated software screens to review thousands of stocks each day for you, to find just the handful that meet his demanding criteria.

Product Features:
  • Daily commentary and coaching on swing trading
  • Technical charts and analysis
Top Rated Stocks Top Rated Funds Top Rated ETFs